As of June 30, 2024, the Company had cash of approximately $1.5 million. Between June 30, 2024 and August 14, 2024, the Company has raised total gross proceeds of approximately $12.4 million of financing, and has sufficient cash to fund its operations through the first quarter of 2025. The Company expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- Biotech Alert: Searches spiking for these stocks today
- CNS Pharmaceuticals Expands Portfolio with Strategic Licensing Deal
- CNS Pharmaceuticals enters license agreement with Cortice Biosciences
- CNS Pharmaceuticals files to sell 2.36M shares of common stock for holders
- CNS Pharmaceuticals prices registered direct offering, private placement